Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Veracyte Inc (NQ: VCYT ) 32.32 -1.16 (-3.46%) Streaming Delayed Price Updated: 11:41 AM EDT, Oct 9, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Veracyte Inc < Previous 1 2 3 4 5 6 7 8 9 10 Next > Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 January 05, 2023 Via Benzinga Expert Ratings for Veracyte January 05, 2023 Via Benzinga Veracyte Earnings Perspective: Return On Capital Employed November 16, 2022 Via Benzinga Data Published in JCEM Demonstrate Strong Real-World Performance of Veracyte’s Afirma GSC in Thyroid Cancer Diagnosis December 15, 2022 From Veracyte, Inc. Via Business Wire Veracyte Stock Showing Market Leadership; Earns 93 RS Rating December 01, 2022 Veracyte shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. Via Investor's Business Daily US Stocks Open Lower; Nasdaq Drops 100 Points November 03, 2022 U.S. stocks traded lower this morning, with the Nasdaq Composite dropping around 100 points on Thursday. The Federal Reserve, on Wednesday, raised interest rates by 75 bps. Via Benzinga Veracyte Announces Third Quarter 2022 Financial Results November 02, 2022 From Veracyte, Inc. Via Business Wire Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday November 11, 2022 Gainers Via Benzinga Why Greenhill Shares Climbed Around 25%; Here Are 100 Biggest Movers From Yesterday November 04, 2022 Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) shares jumped 242.8% to close at $105.72 on Thursday. The company announced a strategic plan to enter into the clean energy industry. Via Benzinga Why Lincoln National Shares Are Trading Lower By 31%? Here Are 72 Stocks Moving In Thursday's Session November 03, 2022 Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) gained 64% to $50.60. Via Benzinga Veracyte Announces Three Abstracts to Be Presented at SITC 2022 Annual Meeting November 01, 2022 From Veracyte, Inc. Via Business Wire Earnings Scheduled For November 2, 2022 November 02, 2022 Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for its second quarter. Via Benzinga Veracyte to Participate in the Credit Suisse 31st Annual Healthcare Conference October 27, 2022 From Veracyte, Inc. Via Business Wire New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose Radiotherapy October 25, 2022 From Veracyte, Inc. Via Business Wire Veracyte Data Presented at ATA Annual Meeting Provide New Insights into Molecular Underpinnings of Thyroid Cancer October 24, 2022 From Veracyte, Inc. Via Business Wire 12 Health Care Stocks Moving In Wednesday's After-Market Session October 19, 2022 Gainers ASLAN Pharma (NASDAQ:ASLN) stock moved upwards by 13.7% to $0.54 during Wednesday's after-market session. The market value of their outstanding shares is at $37.6 million. Via Benzinga New Data Presented at CHEST 2022 Reinforce Clinical Value of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer October 18, 2022 From Veracyte, Inc. Via Business Wire Veracyte to Release Third Quarter 2022 Financial Results on November 2, 2022 October 13, 2022 From Veracyte, Inc. Via Business Wire New Data Published in JNCI Demonstrate Veracyte’s Decipher Prostate Genomic Classifier May Improve Identification of Aggressive Prostate Cancer in African American Men September 22, 2022 From Veracyte, Inc. Via Business Wire Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access September 13, 2022 From Veracyte, Inc. Via Business Wire New Data Presented at ESMO 2022 Show Veracyte’s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer September 11, 2022 From Veracyte, Inc. Via Business Wire New Data Suggest Veracyte’s Envisia Genomic Classifier Can Help Predict Disease Progression in Interstitial Lung Disease Patients Treated with Combination Immunosuppressive Therapy September 07, 2022 From Veracyte, Inc. Via Business Wire Veracyte to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference September 01, 2022 From Veracyte, Inc. Via Business Wire Veracyte Announces Seven Abstracts to Be Presented at ESMO Congress 2022 August 31, 2022 From Veracyte, Inc. Via Business Wire New Data in Nature Medicine Suggest Pre-Treatment Tumor Microenvironment Can Impact Response for CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma August 29, 2022 From Veracyte, Inc. Via Business Wire Whither Small Caps After Fed’s Tough Talk? August 29, 2022 For now its better not to “Fight the Fed” because they are fighting the with the market. Now that everyone is scared of the Fed's rhetoric it would be better to wait a week or so as more data and... Via Talk Markets Veracyte Appoints Eliav Barr, M.D., to Its Board of Directors August 11, 2022 From Veracyte, Inc. Via Business Wire Veracyte: Q2 Earnings Insights August 02, 2022 Veracyte (NASDAQ:VCYT) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Veracyte beat estimated earnings by... Via Benzinga Veracyte Announces Second Quarter 2022 Financial Results August 02, 2022 From Veracyte, Inc. Via Business Wire Earnings Scheduled For August 2, 2022 August 02, 2022 Companies Reporting Before The Bell • Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion. Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 10 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.